As of 30 Sep 2025, 30 institutional investors reported holding $423,204,030 in principal (par value) of SAREPTA THERAPEUTICS INC - NOTE 1.250% 9/1.
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | $0 | $0 | -$1,275,000 | 0 | |
| 2025 Q3 | $423,204,030 | $373,473,256 | -$445,467,137 | 87.97% | 30 |
| 2025 Q2 | $1,009,471,014 | $772,193,004 | -$30,571,515 | 73.43% | 58 |
| 2025 Q1 | $987,578,288 | $920,780,689 | +$32,592,281 | 93.16% | 75 |
| 2024 Q4 | $918,950,180 | $1,045,393,917 | -$29,584,628 | 110.1% | 76 |
| 2024 Q3 | $935,285,828 | $1,096,813,939 | -$3,342,197 | 113.6% | 71 |
| 2024 Q2 | $954,852,856 | $1,268,946,107 | -$94,057,168 | 128.9% | 74 |
| 2024 Q1 | $1,025,219,311 | $1,240,011,569 | -$17,028,924,411 | 116.98% | 62 |
| 2023 Q4 | $0 | $0 | -$47,058,096 | 0 | |
| 2023 Q3 | $954,469,022 | $1,105,756,156 | +$1,105,753,276 | 112.15% | 62 |